Shinpoong Pharm launches paclitaxel injection

Published: 2003-11-25 06:58:00

Updated: 2003-11-25 06:58:00

Shinpoong Pharm said recently that after completion of bioequivalence tests in last May, it launched paclitaxel injection (tradename: Padexol), an antineoplastic agent, which is indicated for treatment of breast cancer, ovarian cancer and lung cancer

According to Shinpoong, Padexol is a 100 pe...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK